Tag: cdnacp

Self-sampling for high-risk human papillomavirus as a follow-up alternative after treatment of high-grade cervical intraepithelial neoplasia

Self-sampling for high-risk human papillomavirus as a follow-up alternative after treatment of high-grade cervical intraepithelial neoplasia

Posted on by Brian Taylor

Women handled for high-grade cervical-intraepithelial-neoplasia (CIN) require long-term follow-up with high-risk human-papillomavirus (HPV) testing. Self-sampling for HPV is well-accepted amongst these sufferers, however its function in follow-up for this group requires investigation. The current research examined how effectively HPV findings from self-sampled vaginal (VSS) and urine specimens appropriately recognized girls from this cohort with recurrent CIN2+ in contrast with samples collected by clinicians. At 1st post-conization follow-up, 531 sufferers (99.8% participation) gave urine samples, carried out VSS, underwent colposcopy with punch biopsy of seen lesions and clinician-collected cervical sampling for HPV evaluation and liquid-based cytology.

A complete of 113 sufferers with optimistic HPV and/or irregular cytology at 1st follow-up underwent 2nd follow-up. At 1st follow-up, all sufferers with recurrent CIN3 had optimistic HPV outcomes by all strategies. Clinician sampling and VSS revealed HPV16 positivity in 50% of recurrent circumstances and urine sampling revealed HPV16 positivity in 25% of recurrent circumstances. At 2nd follow-up, all 7 newly-detected CIN2/three recurrences had been related to HPV positivity on VSS and clinician-samples. Only clinician-collected samples detected HPV positivity for two adenocarcinoma-in-situ recurrences, and each had been HPV18 optimistic.

A complete of 77 sufferers had irregular cytology at 1st follow-up, for which HPV positivity by way of VSS yielded highest sensitivity. The HPV findings had been optimistic from VSS in 12 sufferers with high-grade squamous-intraepithelial-lesions (HSIL), and 11 sufferers with HSIL had optimistic HPV findings in clinician-collected and urine samples. All strategies for assessing HPV presence yielded important age-adjusted odds ratios for predicting irregular lesions at 1st follow-up. For general HPV outcomes, Cohen’s kappa revealed substantial settlement between VSS and clinician sampling, and reasonable settlement between urine and clinician sampling. Clinician sampling and VSS had been extremely concordant for HPV16. Insofar as the pathology was squamous (not glandular), VSS appeared as delicate as clinician sampling for HPV in predicting final result among the many current cohort. Since VSS might be carried out at residence, this selection can maximize participation within the required long-term follow-up for these girls at high-risk.

What each dentist must find out about human papillomavirus

Human papillomavirus (HPV) has a practically ubiquitous prevalence inside the adolescent and grownup populations worldwide. The virus has been implicated for a long time in cervical and uterine cancers, however current information have proven a rise in circumstances of virally associated oropharyngeal squamous cell carcinoma in each female and male cohorts. The goal of this text is to overview the oral well being implications of HPV an infection, together with oral and oropharyngeal prevalence, manifestations, neoplastic potential of HPV-associated head and neck lesions, treatment modalities, and vaccine use.

The article may even focus on the persevering with training wants of oral healthcare suppliers. Dental professionals ought to routinely display screen sufferers for oral and oropharyngeal manifestations of HPV an infection, search well timed referral for therapeutic intervention of doubtlessly malignant lesions, and grow to be sturdy proponents of HPV vaccinations for at-risk sufferers. Human papillomavirus sort 16 (HPV-16) is the key HPV sort concerned in inflicting cervical most cancers amongst girls. The illness burden is excessive in creating and underdeveloped nations. Previously, the constitutive expression of HPV-16 L1 protein led to male sterility in transplastomic tobacco vegetation.

Here, the HPV-16 L1 gene was expressed in chloroplasts of Nicotiana tabacum beneath the management of an ethanol-inducible promoter, trans-activated by nucleus-derived sign peptide. Plants containing nuclear part had been remodeled with transformation vector pEXP-T7-L1 by biolistic gun. The transformation and homoplasmic standing of remodeled vegetation was verified by polymerase chain response (PCR) and Southern blotting, respectively. Protein was induced by spraying 5% ethanol for seven consecutive days. The appropriate folding of L1 protein was confirmed by antigen-capture ELISA utilizing a conformation-specific antibody. The L1 protein amassed as much as three μg/gm of contemporary plant materials.

Self-sampling for high-risk human papillomavirus as a follow-up alternative after treatment of high-grade cervical intraepithelial neoplasia

Human Papillomavirus (HPV) Health Savings as an Alternative Solution: HPV Vaccination Behavior in Adolescents

This research aimed to measure the results of reproductive well being financial savings (tabungan kesehatan reproduksi, Takespro) on human papillomavirus (HPV) vaccine initiation program and the standard of the choice making to get vaccinated, as measured by data, attitudes, beliefs, and self-efficacy towards HPV vaccination.  This quasi-experimental research was carried out on 128 college students randomly allotted to intervention and management teams. This analysis was carried out in junior excessive colleges.
The intervention group acquired the well being training “Takespro HPV” intervention by means of movies and booklets for 6 months at college. Participants within the management group acquired traditional care from the varsity. Data had been collected utilizing a questionnaire of data, attitudes, beliefs, and self-efficacy about HPV vaccination modified by researchers based mostly on earlier analysis and examined for validity and reliability. Data had been analyzed utilizing Mann-Whitney take a look at and impartial t-test.

Stathmin 1 / Oncoprotein 18 Antibody
20-abx115844
  • EUR 732.00
  • EUR 398.00
  • 150 ul
  • 50 ul

99445-18 DCT 18 X 150MM
99445-18 125/pk
EUR 97
Description: Disposable Culture Tubes; DCT's, CGW

Stathmin/Metablastin/Oncoprotein 18
MO47065 0.5 ml
EUR 349

Human Papillomavirus 16 Oncoprotein E7 (HPV16-E7) Antibody
abx414613-02mg 0.2 mg
EUR 565

Human Papillomavirus 16 Oncoprotein E7 (HPV16-E7) Antibody
abx414614-02mg 0.2 mg
EUR 565

Recombinant Human Papillomavirus 18
7-07777 100µg Ask for price

Recombinant Human Papillomavirus 18
7-07778 500µg Ask for price

Recombinant Human Papillomavirus 18
7-07779 1000µg Ask for price

Papillomavirus type 18 Protein E7 Antibody
20-abx110071
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

99999 CAP 18-415
99999-18 1000/pk
EUR 295
Description: Disposable Screw Cap Culture Tubes; DSCCT's, Caps

Mouse Anti Human Papillomavirus 16 Oncoprotein E7 Monoclonal Antibody
CABT-51466MH 0.2 mg
EUR 767

Human papillomavirus 18 PCR kit
PCR-H464-48D 50T
EUR 453

Human papillomavirus 18 PCR kit
PCR-H464-96D 100T
EUR 572

9998 SCREW CAP 415/18
9998-18 192/pk
EUR 103
Description: General Apparatus; Stoppers

Human Papillomavirus Type 18 (HPV 18) ELISA Kit
abx052654-96tests 96 tests
EUR 668

Papillomavirus type 18 Protein E7 Antibody (Biotin)
20-abx105747
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Papillomavirus type 18 Protein E7 Antibody (FITC)
20-abx107165
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Papillomavirus type 18 Protein E7 Antibody (HRP)
20-abx108585
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Human papillomavirus 18 RT PCR kit
RTq-H464-100D 100T
EUR 717

Human papillomavirus 18 RT PCR kit
RTq-H464-150D 150T
EUR 808

Human papillomavirus 18 RT PCR kit
RTq-H464-50D 50T
EUR 598

COVER GLASS, NO. 1, SQUARE 18 X 18MM
2845-18 100/pk
EUR 112
Description: Cover Glass; Cover Glass, CGW

COVER GLASS, NO. 2, SQUARE 18 X 18MM
2855-18 50/pk
EUR 83
Description: Cover Glass; Cover Glass, CGW

COVER GLASS, NO. 1 1/2, SQUARE 18 X 18MM
2850-18 100/pk
EUR 131
Description: Cover Glass; Cover Glass, CGW

Human papillomavirus 18 One-Step PCR kit
Oneq-H464-100D 100T
EUR 866

Human papillomavirus 18 One-Step PCR kit
Oneq-H464-150D 150T
EUR 981

Human papillomavirus 18 One-Step PCR kit
Oneq-H464-50D 50T
EUR 718

Human Papillomavirus Type 18 ?HPV18?ELISA Kit
201-12-2024 96 tests
EUR 440
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Human papillomavirus type 18 L1 protein (L1)
1-CSB-RP083594v
  • EUR 380.00
  • EUR 214.00
  • EUR 1309.00
  • EUR 560.00
  • EUR 873.00
  • EUR 262.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human papillomavirus type 18 L1 protein(L1),partial expressed in E.coli

Human papillomavirus type 18 Protein E7 (E7)
1-CSB-YP361948HMN
  • EUR 430.00
  • EUR 234.00
  • EUR 1508.00
  • EUR 642.00
  • EUR 1009.00
  • EUR 291.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human papillomavirus type 18 Protein E7(E7) expressed in Yeast

Human papillomavirus type 18 Protein E7 (E7)
1-CSB-EP361948HMN
  • EUR 380.00
  • EUR 214.00
  • EUR 1309.00
  • EUR 560.00
  • EUR 873.00
  • EUR 262.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human papillomavirus type 18 Protein E7(E7) expressed in E.coli

Human Papillomavirus Type 18 (HPV18）ELISA Kit
QY-E01728 96T
EUR 394

Human papillomavirus type 18 (HPV18) antibody (IgM) ELISA kit
CSB-EQ028067HU-24T 1 plate of 24 wells
EUR 165
Description: Quantitativesandwich ELISA kit for measuring Human papillomavirus type 18 (HPV18) antibody (IgM) in samples from serum, plasma. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Human papillomavirus type 18 (HPV18) antibody (IgM) ELISA kit
1-CSB-EQ028067HU
  • EUR 804.00
  • EUR 5099.00
  • EUR 2704.00
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Quantitativesandwich ELISA kit for measuring Human papillomavirus type 18 (HPV18) antibody (IgM) in samples from serum, plasma. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Human Papillomavirus Type 18 L1 ?HPV18L1?ELISA Kit
201-12-2025 96 tests
EUR 440
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Human papillomavirus type 18 Regulatory protein E2 (E2)
1-CSB-YP361949HMN
  • EUR 430.00
  • EUR 234.00
  • EUR 1508.00
  • EUR 642.00
  • EUR 1009.00
  • EUR 291.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human papillomavirus type 18 Regulatory protein E2(E2) expressed in Yeast

Human papillomavirus type 18 Regulatory protein E2 (E2)
1-CSB-EP361949HMN
  • EUR 380.00
  • EUR 214.00
  • EUR 1309.00
  • EUR 560.00
  • EUR 873.00
  • EUR 262.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human papillomavirus type 18 Regulatory protein E2(E2) expressed in E.coli

Human Papillomavirus Type 18 L1(HPV18L1）ELISA Kit
QY-E01727 96T
EUR 394

ELISA kit for Human papillomavirus type 18 (HPV18)antibody (IgG)
EK0272 96 tests
EUR 712
Description: Enzyme-linked immunosorbent assay kit for quantification of Human papillomavirus type 18 (HPV18)antibody (IgG) in samples from serum, plasma, tissue homogenates and other biological fluids.

Rabbit papillomavirus type 18 L1-capsids antibody(IgG)ELISA Kit
CSB-E14280Rb-24T 1 plate of 24 wells
EUR 165
Description: Quantitativesandwich ELISA kit for measuring Rabbit papillomavirus type 18 L1-capsids antibody (IgG) in samples from serum, plasma, cell culture supernates, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Rabbit papillomavirus type 18 L1-capsids antibody(IgG)ELISA Kit
1-CSB-E14280Rb
  • EUR 900.00
  • EUR 5476.00
  • EUR 2900.00
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Quantitativesandwich ELISA kit for measuring Rabbit papillomavirus type 18 L1-capsids antibody(IgG) in samples from serum, plasma, cell culture supernates, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Human Papillomavirus Type 18-IgG (HPV18-IgG) ELISA Kit
abx051563-96tests 96 tests
EUR 668

Human papillomavirus type 18 Minor capsid protein L2 (L2)
1-CSB-YP356939HMN
  • EUR 430.00
  • EUR 234.00
  • EUR 1508.00
  • EUR 642.00
  • EUR 1009.00
  • EUR 291.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human papillomavirus type 18 Minor capsid protein L2(L2) expressed in Yeast

Human papillomavirus type 18 Minor capsid protein L2 (L2)
1-CSB-EP356939HMN
  • EUR 380.00
  • EUR 214.00
  • EUR 1309.00
  • EUR 560.00
  • EUR 873.00
  • EUR 262.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human papillomavirus type 18 Minor capsid protein L2(L2) expressed in E.coli

ELISA kit for Rabbit Papillomavirus type 18 L1-capsids IgG antibody
KTE90138-48T 48T
EUR 354
Description: Quantitative sandwich ELISA for measuring Rabbit Papillomavirus type 18 L1-capsids IgG antibody in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

ELISA kit for Rabbit Papillomavirus type 18 L1-capsids IgG antibody
KTE90138-5platesof96wells 5 plates of 96 wells
EUR 2252
Description: Quantitative sandwich ELISA for measuring Rabbit Papillomavirus type 18 L1-capsids IgG antibody in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

ELISA kit for Rabbit Papillomavirus type 18 L1-capsids IgG antibody
KTE90138-96T 96T
EUR 572
Description: Quantitative sandwich ELISA for measuring Rabbit Papillomavirus type 18 L1-capsids IgG antibody in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Human papillomavirus type 18 L1-capsids(HPV18L1) antibody (IgG) ELISA kit
CSB-EQ027476HU-24T 1 plate of 24 wells
EUR 165
Description: Qualitative indirect ELISA kit for measuring Human papillomavirus type 18 L1-capsids (HPV18L1) antibody (IgG) in samples from serum, plasma. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Human papillomavirus type 18 L1-capsids(HPV18L1) antibody (IgG) ELISA kit
1-CSB-EQ027476HU
  • EUR 602.00
  • EUR 4238.00
  • EUR 2256.00
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Qualitative indirect ELISA kit for measuring Human papillomavirus type 18 L1-capsids(HPV18L1) antibody (IgG) in samples from serum, plasma. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

FT4 (Free thyroxine) ELISA test
18 96T/Box Ask for price
Description: ELISA based test for quantitative detection of FT4 (Free thyroxine)

ELISA kit for Human papillomavirus type 18 L1-capsids (HPV18L1) antibody (IgG)
EK0271 96 tests
EUR 712
Description: Enzyme-linked immunosorbent assay kit for quantification of Human papillomavirus type 18 L1-capsids (HPV18L1) antibody (IgG) in samples from serum, plasma, tissue homogenates and other biological fluids.

Goat Anti-Papillomavirus Polyclonal antibody
CABT-RM239 500 µl
EUR 408

Goat polyclonal antibody for Papillomavirus
5001 1 ml
EUR 316.44
Description: This is goat polyclonal antibody against Papillomavirus group for WB, ELISA.

Mouse antibody for Bovine Papillomavirus
5091 100 ug
EUR 321.88
Description: This is purified Mouse monoclonal antibody against Bovine Papillomavirus for WB, ELISA.

Mouse antibody for Bovine Papillomavirus
5095 100 ug
EUR 321.88
Description: This is purified Mouse monoclonal antibody against Bovine Papillomavirus for WB, ELISA.

Goat polyclonal antibody for Papillomavirus
6124 1 ml
EUR 321.88
Description: This is HRP conjugated goat polyclonal antibody against Papillomavirus group for WB, ELISA.

Papillomavirus 16 Protein
20-abx260289
  • EUR 885.00
  • EUR 342.00
  • EUR 1609.00
  • 0.5 mg
  • 100 ug
  • 1 mg

Papillomavirus 6 Protein
20-abx260291
  • EUR 885.00
  • EUR 342.00
  • EUR 1609.00
  • 0.5 mg
  • 100 ug
  • 1 mg

Papillomavirus 11 Protein
20-abx260292
  • EUR 885.00
  • EUR 342.00
  • EUR 1609.00
  • 0.5 mg
  • 100 ug
  • 1 mg

Anti-c-Myc Oncoprotein Monoclonal Antibody
M00026 100ug/vial
EUR 397
Description: Mouse Monoclonal c-Myc Oncoprotein Antibody. Validated in IHC and tested in Human.

Oncoprotein Induced Transcript 3 (OIT3) Antibody
20-abx130349
  • EUR 439.00
  • EUR 133.00
  • EUR 1233.00
  • EUR 592.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Oncoprotein Induced Transcript 3 (OIT3) Antibody
20-abx103361
  • EUR 411.00
  • EUR 133.00
  • EUR 1149.00
  • EUR 565.00
  • EUR 314.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCA1269-250 250uL
EUR 383
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), APC conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC811269-100 100uL
EUR 199
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC811269-500 500uL
EUR 544
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCAP1269-100 100uL
EUR 199
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCAP1269-500 500uL
EUR 544
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCB1269-100 100uL
EUR 199
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Biotin conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCB1269-500 500uL
EUR 544
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Biotin conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC471269-100 100uL
EUR 199
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF647 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC471269-500 500uL
EUR 544
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF647 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC551269-100 100uL
EUR 199
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC551269-500 500uL
EUR 544
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC431269-100 100uL
EUR 199
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC431269-500 500uL
EUR 544
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC881269-100 100uL
EUR 199
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF488A conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC881269-500 500uL
EUR 544
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF488A conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC941269-100 100uL
EUR 199
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF594 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC941269-500 500uL
EUR 544
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF594 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCH1269-100 100uL
EUR 199
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCH1269-500 500uL
EUR 544
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCP1269-250 250uL
EUR 383
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), PerCP conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC041269-100 100uL
EUR 199
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF405S conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC041269-500 500uL
EUR 544
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF405S conjugate, Concentration: 0.1mg/mL

Oncoprotein Induced Transcript 3 (OIT3) Antibody
20-abx173889
  • EUR 815.00
  • EUR 425.00
  • 1 mg
  • 200 ug

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCR1269-250 250uL
EUR 383
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), RPE conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNUB1269-100 100uL
EUR 209
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Concentration: 0.2mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNUB1269-500 500uL
EUR 458
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Concentration: 0.2mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC681269-100 100uL
EUR 199
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF568 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC681269-500 500uL
EUR 544
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF568 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC701269-100 100uL
EUR 199
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF770 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC701269-500 500uL
EUR 544
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF770 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC051269-100 100uL
EUR 199
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC051269-500 500uL
EUR 544
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC611269-100 100uL
EUR 199
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC611269-500 500uL
EUR 544
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC401269-100 100uL
EUR 199
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF640R conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC401269-500 500uL
EUR 544
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF640R conjugate, Concentration: 0.1mg/mL
A complete of 40 contributors had been actively enrolled within the intervention group, and 88 had been passively enrolled within the management group. The well being training that was half of the Takespro HPV intervention improved the data (p < 0.05) and self-efficacy (p < 0.05) of the intervention group in contrast with the management group. The perspective and perception variables confirmed no important distinction (p > 0.05). Forty college students exhibited the well being copy financial savings conduct at colleges. However, the financial savings quantity was inadequate to get HPV vaccination on the initiation part.